Anti-Her-2/neu antibody induces apoptosis in Her-2/neu overexpressing breast cancer cells independently from p53 status

被引：20

作者：

Brodowicz, T

Kandioler, D

Tomek, S

Ludwig, C

Rudas, M

Kunstfeld, R

Koestler, W

Hejna, M

Budinsky, A

Krainer, M

Wiltschke, C

Zielinski, CC ^{[1
]}

机构：

[1] Univ Hosp Vienna, Clin Div Oncol, Vienna, Austria

[2] Univ Hosp Vienna, Chair Med Expt Oncol, Dept Med 1, Vienna, Austria

[3] Univ Hosp Vienna, Dept Surg, Clin Div Gen Surg, Vienna, Austria

[4] Univ Hosp Vienna, Dept Pathol, Clin Div Clin Pathol, Vienna, Austria

[5] Ludwig Boltzman Inst Clin Expt Oncol, Vienna, Austria

来源：

BRITISH JOURNAL OF CANCER | 2001年 / 85卷 / 11期

关键词：

apoptosis; bcl-2; breast cancer; HER-2/neu; p53;

D O I：

10.1054/bjoc.2001.2197

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Anti-Her-2/neu antibody is known to induce apoptosis in HER-2/neu overexpressing breast cancer cells. However, exact regulatory mechanisms mediating and controlling this phenomenon are still unknown. In the present study, we have investigated the effect of anti-Her-2/neu antibody on apoptosis of HER-2/neu overexpressing human breast cancer cell lines SK-BR-3, HTB-24, HTB-25, HTB-27, HTIB-128, HTB-130 and HTB-131 in relation to p53 genotype and bcl-2 status. SK-BR-3, HTIB-24, HTB-128 and HTB-130 cells exhibited mutant p53, whereas wild type p53 was found in HTB-25, HTB-27 and HTB-131 cells. All seven cell lines weakly expressed bcl-2 protein (10-20%). Anti-Her-2/neu antibody, irrespective of p53 and bcl-2 status, induced apoptosis in all 7 cell lines dose- and time-dependently and correlated with Her-2/neu overexpression. In addition. incubation of cell lines with anti-Her-2/neu antibody did not alter p53 or bcl-2 expression. Anti-HER-2/neu antibody did not induce apoptosis in HER-2/neu negative HBL-100 and HTB-132 cell lines. Our results indicate that within the panel of tested breast cancer cell lines, anti-Her-2/neu antibody-induced apoptosis was independent from the presence of intact p53. 0 2001 Cancer Research Compaign.

引用

页码：1764 / 1770

页数：7

共 59 条

[1] Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients [J].

Aas, T ;

Borresen, AL ;

Geisler, S ;

SmithSorensen, B ;

Johnsen, H ;

Varhaug, JE ;

Akslen, LA ;

Lonning, PE .

NATURE MEDICINE, 1996, 2 (07) :811-814

[2] Bcl-2 inhibits p53 nuclear import following DNA damage [J].

Beham, A ;

Marin, MC ;

Fernandez, A ;

Herrmann, J ;

Brisbay, S ;

Tari, AM ;

LopezBerestein, G ;

Lozano, G ;

Sarkiss, M ;

McDonnell, TJ .

ONCOGENE, 1997, 15 (23) :2767-2772

[3] COMPLETE SEQUENCING OF THE P53 GENE PROVIDES PROGNOSTIC INFORMATION IN BREAST-CANCER PATIENTS, PARTICULARLY IN RELATION TO ADJUVANT SYSTEMIC THERAPY AND RADIOTHERAPY [J].

BERGH, J ;

NORBERG, T ;

SJOGREN, S ;

LINDGREN, A ;

HOLMBERG, L .

NATURE MEDICINE, 1995, 1 (10) :1029-1034

[4]

BRACEY TS, 1995, ONCOGENE, V10, P2391

[5]

Brodowicz T, 1997, INT J CANCER, V73, P875, DOI 10.1002/(SICI)1097-0215(19971210)73:6<875::AID-IJC19>3.0.CO

[6]

2-3

[7] Inhibition of proliferation and induction of apoptosis in soft tissue sarcoma cells by interferon-α and retinoids [J].

Brodowicz, T ;

Wiltschke, C ;

Kandioler-Eckersberger, D ;

Grunt, TW ;

Rudas, M ;

Schneider, SM ;

Hejna, M ;

Budinsky, A ;

Zielinski, CC .

BRITISH JOURNAL OF CANCER, 1999, 80 (09) :1350-1358

[8]

Brown JL, 1998, ANIM REPROD SCI, V53, P1

[9] INDUCTION OF THE GROWTH INHIBITOR IGF-BINDING PROTEIN-3 BY P53 [J].

BUCKBINDER, L ;

TALBOTT, R ;

VELASCOMIGUEL, S ;

TAKENAKA, I ;

FAHA, B ;

SEIZINGER, BR ;

KLEY, N .

NATURE, 1995, 377 (6550) :646-649

[10] Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer [J].

Burstein, HJ ;

Kuter, I ;

Campos, SM ;

Gelman, RS ;

Tribou, L ;

Parker, LM ;

Manola, J ;

Younger, J ;

Matulonis, U ;

Bunnell, CA ;

Partridge, AH ;

Richardson, PG ;

Clarke, K ;

Shulman, LN ;

Winer, EP .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (10) :2722-2730

← 1 2 3 4 5 6 →